

-20-

**WE CLAIM:**

1. Crystalline 2,5-dione-3-(1-methyl-1H-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl]-1H-pyrrole mono-hydrochloride, a  
5 hydrate thereof, or mixtures thereof.
2. Crystalline 2,5-dione-3-(1-methyl-1H-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl]-1H-pyrrole mono-hydrochloride, a  
10 hydrate thereof, or mixtures thereof, having an X-ray diffraction pattern which comprises the following peaks:  $6.8 \pm 0.1$ ,  $10.9 \pm 0.1$ ,  $14.2 \pm 0.1$  and  $16.6 \pm 0.1^\circ$  in  $2\theta$ ; when the pattern is obtained from a copper radiation source ( $\text{CuK}\alpha$ ;  $\lambda = 1.54056 \text{ \AA}$ ).
3. The crystalline mono-hydrochloride of claim 2 having an X-ray diffraction  
15 pattern which further comprises the following peaks:  $6.3 \pm 0.1$ ,  $7.2 \pm 0.1$ ,  $12.5 \pm 0.1$  and  $17.0 \pm 0.1^\circ$  in  $2\theta$ .
4. A pharmaceutical composition comprising a salt of any one of claims 1-3 and a pharmaceutical carrier.  
20
5. A method of treating non-Hodgkins lymphoma which comprises administering to a mammal in need thereof an effective amount of a compound of any one of claims 1-3.
6. A method of treating glioblastoma which comprises administering to a mammal in need thereof an effective amount of a compound of any one of claims 1-3.  
25
7. A method of treating non-small cell lung cancer which comprises administering to a mammal in need thereof an effective amount of a compound of any one of claims 1-3.  
30

-21-

8. The compound of any one of claims 1-3 for use in a method of treating a human body by therapy.
9. The compound of claim 8 for use in treating non-Hodgkins lymphoma.  
5
10. The compound of claim 8 for use in treating glioblastoma.
11. The compound of claim 8 for use in treating non-small cell lung cancer.
- 10 12. The use of a compound of any one of claims 1-3 for the manufacture of a medicament for the treatment of non-Hodgkins lymphoma.
13. The use of a compound of any one of claims 1-3 for the manufacture of a medicament for the treatment of glioblastoma.  
15
14. The use of a compound of any one of claims 1-3 for the manufacture of a medicament for the treatment of non-small cell lung cancer.